Showing 1–11 of 11 results for author: Eddy, J

BraTS-PEDs: Results of the Multi-Consortium International Pediatric Brain Tumor Segmentation Challenge 2023

Authors: Anahita Fathi Kazerooni, Nastaran Khalili, Xinyang Liu, Debanjan Haldar, Zhifan Jiang, Anna Zapaishchykova, Julija Pavaine, Lubdha M. Shah, Blaise V. Jones, Nakul Sheth, Sanjay P. Prabhu, Aaron S. McAllister, Wenxin Tu, Khanak K. Nandolia, Andres F. Rodriguez, Ibraheem Salman Shaikh, Mariana Sanchez Montano, Hollie Anne Lai, Maruf Adewole, Jake Albrecht, Udunna Anazodo, Hannah Anderson, Syed Muhammed Anwar, Alejandro Aristizabal, Sina Bagheri , et al. (55 additional authors not shown)

Abstract: Pediatric central nervous system tumors are the leading cause of cancer-related deaths in children. The five-year survival rate for high-grade glioma in children is less than 20%. The development of new treatments is dependent upon multi-institutional collaborative clinical trials requiring reproducible and accurate centralized response assessment. We present the results of the BraTS-PEDs 2023 cha… ▽ More Pediatric central nervous system tumors are the leading cause of cancer-related deaths in children. The five-year survival rate for high-grade glioma in children is less than 20%. The development of new treatments is dependent upon multi-institutional collaborative clinical trials requiring reproducible and accurate centralized response assessment. We present the results of the BraTS-PEDs 2023 challenge, the first Brain Tumor Segmentation (BraTS) challenge focused on pediatric brain tumors. This challenge utilized data acquired from multiple international consortia dedicated to pediatric neuro-oncology and clinical trials. BraTS-PEDs 2023 aimed to evaluate volumetric segmentation algorithms for pediatric brain gliomas from magnetic resonance imaging using standardized quantitative performance evaluation metrics employed across the BraTS 2023 challenges. The top-performing AI approaches for pediatric tumor analysis included ensembles of nnU-Net and Swin UNETR, Auto3DSeg, or nnU-Net with a self-supervised framework. The BraTSPEDs 2023 challenge fostered collaboration between clinicians (neuro-oncologists, neuroradiologists) and AI/imaging scientists, promoting faster data sharing and the development of automated volumetric analysis techniques. These advancements could significantly benefit clinical trials and improve the care of children with brain tumors. △ Less

Submitted 16 July, 2024; v1 submitted 11 July, 2024; originally announced July 2024.

Analysis of the BraTS 2023 Intracranial Meningioma Segmentation Challenge

Authors: Dominic LaBella, Ujjwal Baid, Omaditya Khanna, Shan McBurney-Lin, Ryan McLean, Pierre Nedelec, Arif Rashid, Nourel Hoda Tahon, Talissa Altes, Radhika Bhalerao, Yaseen Dhemesh, Devon Godfrey, Fathi Hilal, Scott Floyd, Anastasia Janas, Anahita Fathi Kazerooni, John Kirkpatrick, Collin Kent, Florian Kofler, Kevin Leu, Nazanin Maleki, Bjoern Menze, Maxence Pajot, Zachary J. Reitman, Jeffrey D. Rudie , et al. (96 additional authors not shown)

Abstract: We describe the design and results from the BraTS 2023 Intracranial Meningioma Segmentation Challenge. The BraTS Meningioma Challenge differed from prior BraTS Glioma challenges in that it focused on meningiomas, which are typically benign extra-axial tumors with diverse radiologic and anatomical presentation and a propensity for multiplicity. Nine participating teams each developed deep-learning… ▽ More We describe the design and results from the BraTS 2023 Intracranial Meningioma Segmentation Challenge. The BraTS Meningioma Challenge differed from prior BraTS Glioma challenges in that it focused on meningiomas, which are typically benign extra-axial tumors with diverse radiologic and anatomical presentation and a propensity for multiplicity. Nine participating teams each developed deep-learning automated segmentation models using image data from the largest multi-institutional systematically expert annotated multilabel multi-sequence meningioma MRI dataset to date, which included 1000 training set cases, 141 validation set cases, and 283 hidden test set cases. Each case included T2, T2/FLAIR, T1, and T1Gd brain MRI sequences with associated tumor compartment labels delineating enhancing tumor, non-enhancing tumor, and surrounding non-enhancing T2/FLAIR hyperintensity. Participant automated segmentation models were evaluated and ranked based on a scoring system evaluating lesion-wise metrics including dice similarity coefficient (DSC) and 95% Hausdorff Distance. The top ranked team had a lesion-wise median dice similarity coefficient (DSC) of 0.976, 0.976, and 0.964 for enhancing tumor, tumor core, and whole tumor, respectively and a corresponding average DSC of 0.899, 0.904, and 0.871, respectively. These results serve as state-of-the-art benchmarks for future pre-operative meningioma automated segmentation algorithms. Additionally, we found that 1286 of 1424 cases (90.3%) had at least 1 compartment voxel abutting the edge of the skull-stripped image edge, which requires further investigation into optimal pre-processing face anonymization steps. △ Less

Submitted 15 May, 2024; originally announced May 2024.

Comments: 16 pages, 11 tables, 10 figures, MICCAI

The Brain Tumor Segmentation in Pediatrics (BraTS-PEDs) Challenge: Focus on Pediatrics (CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs)

Authors: Anahita Fathi Kazerooni, Nastaran Khalili, Xinyang Liu, Deep Gandhi, Zhifan Jiang, Syed Muhammed Anwar, Jake Albrecht, Maruf Adewole, Udunna Anazodo, Hannah Anderson, Ujjwal Baid, Timothy Bergquist, Austin J. Borja, Evan Calabrese, Verena Chung, Gian-Marco Conte, Farouk Dako, James Eddy, Ivan Ezhov, Ariana Familiar, Keyvan Farahani, Andrea Franson, Anurag Gottipati, Shuvanjan Haldar, Juan Eugenio Iglesias , et al. (46 additional authors not shown)

Abstract: Pediatric tumors of the central nervous system are the most common cause of cancer-related death in children. The five-year survival rate for high-grade gliomas in children is less than 20%. Due to their rarity, the diagnosis of these entities is often delayed, their treatment is mainly based on historic treatment concepts, and clinical trials require multi-institutional collaborations. Here we pr… ▽ More Pediatric tumors of the central nervous system are the most common cause of cancer-related death in children. The five-year survival rate for high-grade gliomas in children is less than 20%. Due to their rarity, the diagnosis of these entities is often delayed, their treatment is mainly based on historic treatment concepts, and clinical trials require multi-institutional collaborations. Here we present the CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs challenge, focused on pediatric brain tumors with data acquired across multiple international consortia dedicated to pediatric neuro-oncology and clinical trials. The CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs challenge brings together clinicians and AI/imaging scientists to lead to faster development of automated segmentation techniques that could benefit clinical trials, and ultimately the care of children with brain tumors. △ Less

Submitted 11 July, 2024; v1 submitted 23 April, 2024; originally announced April 2024.

Comments: arXiv admin note: substantial text overlap with arXiv:2305.17033

Evaluation of software impact designed for biomedical research: Are we measuring what's meaningful?

Authors: Awan Afiaz, Andrey Ivanov, John Chamberlin, David Hanauer, Candace Savonen, Mary J Goldman, Martin Morgan, Michael Reich, Alexander Getka, Aaron Holmes, Sarthak Pati, Dan Knight, Paul C. Boutros, Spyridon Bakas, J. Gregory Caporaso, Guilherme Del Fiol, Harry Hochheiser, Brian Haas, Patrick D. Schloss, James A. Eddy, Jake Albrecht, Andrey Fedorov, Levi Waldron, Ava M. Hoffman, Richard L. Bradshaw , et al. (2 additional authors not shown)

Abstract: Software is vital for the advancement of biology and medicine. Analysis of usage and impact metrics can help developers determine user and community engagement, justify additional funding, encourage additional use, identify unanticipated use cases, and help define improvement areas. However, there are challenges associated with these analyses including distorted or misleading metrics, as well as e… ▽ More Software is vital for the advancement of biology and medicine. Analysis of usage and impact metrics can help developers determine user and community engagement, justify additional funding, encourage additional use, identify unanticipated use cases, and help define improvement areas. However, there are challenges associated with these analyses including distorted or misleading metrics, as well as ethical and security concerns. More attention to the nuances involved in capturing impact across the spectrum of biological software is needed. Furthermore, some tools may be especially beneficial to a small audience, yet may not have compelling typical usage metrics. We propose more general guidelines, as well as strategies for more specific types of software. We highlight outstanding issues regarding how communities measure or evaluate software impact. To get a deeper understanding of current practices for software evaluations, we performed a survey of participants in the Informatics Technology for Cancer Research (ITCR) program funded by the National Cancer Institute (NCI). We also investigated software among this community and others to assess how often infrastructure that supports such evaluations is implemented and how this impacts rates of papers describing usage of the software. We find that developers recognize the utility of analyzing software usage, but struggle to find the time or funding for such analyses. We also find that infrastructure such as social media presence, more in-depth documentation, the presence of software health metrics, and clear information on how to contact developers seem to be associated with increased usage rates. Our findings can help scientific software developers make the most out of evaluations of their software. △ Less

Submitted 5 June, 2023; originally announced June 2023.

Comments: 25 total pages (17 pages for manuscript and 8 pages for the supplement). There are 2 figures

The Brain Tumor Segmentation (BraTS) Challenge 2023: Glioma Segmentation in Sub-Saharan Africa Patient Population (BraTS-Africa)

Authors: Maruf Adewole, Jeffrey D. Rudie, Anu Gbadamosi, Oluyemisi Toyobo, Confidence Raymond, Dong Zhang, Olubukola Omidiji, Rachel Akinola, Mohammad Abba Suwaid, Adaobi Emegoakor, Nancy Ojo, Kenneth Aguh, Chinasa Kalaiwo, Gabriel Babatunde, Afolabi Ogunleye, Yewande Gbadamosi, Kator Iorpagher, Evan Calabrese, Mariam Aboian, Marius Linguraru, Jake Albrecht, Benedikt Wiestler, Florian Kofler, Anastasia Janas, Dominic LaBella , et al. (26 additional authors not shown)

Abstract: Gliomas are the most common type of primary brain tumors. Although gliomas are relatively rare, they are among the deadliest types of cancer, with a survival rate of less than 2 years after diagnosis. Gliomas are challenging to diagnose, hard to treat and inherently resistant to conventional therapy. Years of extensive research to improve diagnosis and treatment of gliomas have decreased mortality… ▽ More Gliomas are the most common type of primary brain tumors. Although gliomas are relatively rare, they are among the deadliest types of cancer, with a survival rate of less than 2 years after diagnosis. Gliomas are challenging to diagnose, hard to treat and inherently resistant to conventional therapy. Years of extensive research to improve diagnosis and treatment of gliomas have decreased mortality rates across the Global North, while chances of survival among individuals in low- and middle-income countries (LMICs) remain unchanged and are significantly worse in Sub-Saharan Africa (SSA) populations. Long-term survival with glioma is associated with the identification of appropriate pathological features on brain MRI and confirmation by histopathology. Since 2012, the Brain Tumor Segmentation (BraTS) Challenge have evaluated state-of-the-art machine learning methods to detect, characterize, and classify gliomas. However, it is unclear if the state-of-the-art methods can be widely implemented in SSA given the extensive use of lower-quality MRI technology, which produces poor image contrast and resolution and more importantly, the propensity for late presentation of disease at advanced stages as well as the unique characteristics of gliomas in SSA (i.e., suspected higher rates of gliomatosis cerebri). Thus, the BraTS-Africa Challenge provides a unique opportunity to include brain MRI glioma cases from SSA in global efforts through the BraTS Challenge to develop and evaluate computer-aided-diagnostic (CAD) methods for the detection and characterization of glioma in resource-limited settings, where the potential for CAD tools to transform healthcare are more likely. △ Less

Submitted 30 May, 2023; originally announced May 2023.

Comments: arXiv admin note: text overlap with arXiv:2107.02314

The Brain Tumor Segmentation (BraTS) Challenge 2023: Focus on Pediatrics (CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs)

Authors: Anahita Fathi Kazerooni, Nastaran Khalili, Xinyang Liu, Debanjan Haldar, Zhifan Jiang, Syed Muhammed Anwar, Jake Albrecht, Maruf Adewole, Udunna Anazodo, Hannah Anderson, Sina Bagheri, Ujjwal Baid, Timothy Bergquist, Austin J. Borja, Evan Calabrese, Verena Chung, Gian-Marco Conte, Farouk Dako, James Eddy, Ivan Ezhov, Ariana Familiar, Keyvan Farahani, Shuvanjan Haldar, Juan Eugenio Iglesias, Anastasia Janas , et al. (48 additional authors not shown)

Abstract: Pediatric tumors of the central nervous system are the most common cause of cancer-related death in children. The five-year survival rate for high-grade gliomas in children is less than 20\%. Due to their rarity, the diagnosis of these entities is often delayed, their treatment is mainly based on historic treatment concepts, and clinical trials require multi-institutional collaborations. The MICCA… ▽ More Pediatric tumors of the central nervous system are the most common cause of cancer-related death in children. The five-year survival rate for high-grade gliomas in children is less than 20\%. Due to their rarity, the diagnosis of these entities is often delayed, their treatment is mainly based on historic treatment concepts, and clinical trials require multi-institutional collaborations. The MICCAI Brain Tumor Segmentation (BraTS) Challenge is a landmark community benchmark event with a successful history of 12 years of resource creation for the segmentation and analysis of adult glioma. Here we present the CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs 2023 challenge, which represents the first BraTS challenge focused on pediatric brain tumors with data acquired across multiple international consortia dedicated to pediatric neuro-oncology and clinical trials. The BraTS-PEDs 2023 challenge focuses on benchmarking the development of volumentric segmentation algorithms for pediatric brain glioma through standardized quantitative performance evaluation metrics utilized across the BraTS 2023 cluster of challenges. Models gaining knowledge from the BraTS-PEDs multi-parametric structural MRI (mpMRI) training data will be evaluated on separate validation and unseen test mpMRI dataof high-grade pediatric glioma. The CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs 2023 challenge brings together clinicians and AI/imaging scientists to lead to faster development of automated segmentation techniques that could benefit clinical trials, and ultimately the care of children with brain tumors. △ Less

Submitted 23 May, 2024; v1 submitted 26 May, 2023; originally announced May 2023.

The Brain Tumor Segmentation (BraTS) Challenge 2023: Brain MR Image Synthesis for Tumor Segmentation (BraSyn)

Authors: Hongwei Bran Li, Gian Marco Conte, Syed Muhammad Anwar, Florian Kofler, Ivan Ezhov, Koen van Leemput, Marie Piraud, Maria Diaz, Byrone Cole, Evan Calabrese, Jeff Rudie, Felix Meissen, Maruf Adewole, Anastasia Janas, Anahita Fathi Kazerooni, Dominic LaBella, Ahmed W. Moawad, Keyvan Farahani, James Eddy, Timothy Bergquist, Verena Chung, Russell Takeshi Shinohara, Farouk Dako, Walter Wiggins, Zachary Reitman , et al. (43 additional authors not shown)

Abstract: Automated brain tumor segmentation methods have become well-established and reached performance levels offering clear clinical utility. These methods typically rely on four input magnetic resonance imaging (MRI) modalities: T1-weighted images with and without contrast enhancement, T2-weighted images, and FLAIR images. However, some sequences are often missing in clinical practice due to time const… ▽ More Automated brain tumor segmentation methods have become well-established and reached performance levels offering clear clinical utility. These methods typically rely on four input magnetic resonance imaging (MRI) modalities: T1-weighted images with and without contrast enhancement, T2-weighted images, and FLAIR images. However, some sequences are often missing in clinical practice due to time constraints or image artifacts, such as patient motion. Consequently, the ability to substitute missing modalities and gain segmentation performance is highly desirable and necessary for the broader adoption of these algorithms in the clinical routine. In this work, we present the establishment of the Brain MR Image Synthesis Benchmark (BraSyn) in conjunction with the Medical Image Computing and Computer-Assisted Intervention (MICCAI) 2023. The primary objective of this challenge is to evaluate image synthesis methods that can realistically generate missing MRI modalities when multiple available images are provided. The ultimate aim is to facilitate automated brain tumor segmentation pipelines. The image dataset used in the benchmark is diverse and multi-modal, created through collaboration with various hospitals and research institutions. △ Less

Submitted 28 June, 2023; v1 submitted 15 May, 2023; originally announced May 2023.

Comments: Technical report of BraSyn

The Brain Tumor Segmentation (BraTS) Challenge 2023: Local Synthesis of Healthy Brain Tissue via Inpainting

Authors: Florian Kofler, Felix Meissen, Felix Steinbauer, Robert Graf, Eva Oswald, Ezequiel de da Rosa, Hongwei Bran Li, Ujjwal Baid, Florian Hoelzl, Oezguen Turgut, Izabela Horvath, Diana Waldmannstetter, Christina Bukas, Maruf Adewole, Syed Muhammad Anwar, Anastasia Janas, Anahita Fathi Kazerooni, Dominic LaBella, Ahmed W Moawad, Keyvan Farahani, James Eddy, Timothy Bergquist, Verena Chung, Russell Takeshi Shinohara, Farouk Dako , et al. (43 additional authors not shown)

Abstract: A myriad of algorithms for the automatic analysis of brain MR images is available to support clinicians in their decision-making. For brain tumor patients, the image acquisition time series typically starts with a scan that is already pathological. This poses problems, as many algorithms are designed to analyze healthy brains and provide no guarantees for images featuring lesions. Examples include… ▽ More A myriad of algorithms for the automatic analysis of brain MR images is available to support clinicians in their decision-making. For brain tumor patients, the image acquisition time series typically starts with a scan that is already pathological. This poses problems, as many algorithms are designed to analyze healthy brains and provide no guarantees for images featuring lesions. Examples include but are not limited to algorithms for brain anatomy parcellation, tissue segmentation, and brain extraction. To solve this dilemma, we introduce the BraTS 2023 inpainting challenge. Here, the participants' task is to explore inpainting techniques to synthesize healthy brain scans from lesioned ones. The following manuscript contains the task formulation, dataset, and submission procedure. Later it will be updated to summarize the findings of the challenge. The challenge is organized as part of the BraTS 2023 challenge hosted at the MICCAI 2023 conference in Vancouver, Canada. △ Less

Submitted 9 August, 2023; v1 submitted 15 May, 2023; originally announced May 2023.

Comments: 5 pages, 1 figure

The ASNR-MICCAI Brain Tumor Segmentation (BraTS) Challenge 2023: Intracranial Meningioma

Authors: Dominic LaBella, Maruf Adewole, Michelle Alonso-Basanta, Talissa Altes, Syed Muhammad Anwar, Ujjwal Baid, Timothy Bergquist, Radhika Bhalerao, Sully Chen, Verena Chung, Gian-Marco Conte, Farouk Dako, James Eddy, Ivan Ezhov, Devon Godfrey, Fathi Hilal, Ariana Familiar, Keyvan Farahani, Juan Eugenio Iglesias, Zhifan Jiang, Elaine Johanson, Anahita Fathi Kazerooni, Collin Kent, John Kirkpatrick, Florian Kofler , et al. (35 additional authors not shown)

Abstract: Meningiomas are the most common primary intracranial tumor in adults and can be associated with significant morbidity and mortality. Radiologists, neurosurgeons, neuro-oncologists, and radiation oncologists rely on multiparametric MRI (mpMRI) for diagnosis, treatment planning, and longitudinal treatment monitoring; yet automated, objective, and quantitative tools for non-invasive assessment of men… ▽ More Meningiomas are the most common primary intracranial tumor in adults and can be associated with significant morbidity and mortality. Radiologists, neurosurgeons, neuro-oncologists, and radiation oncologists rely on multiparametric MRI (mpMRI) for diagnosis, treatment planning, and longitudinal treatment monitoring; yet automated, objective, and quantitative tools for non-invasive assessment of meningiomas on mpMRI are lacking. The BraTS meningioma 2023 challenge will provide a community standard and benchmark for state-of-the-art automated intracranial meningioma segmentation models based on the largest expert annotated multilabel meningioma mpMRI dataset to date. Challenge competitors will develop automated segmentation models to predict three distinct meningioma sub-regions on MRI including enhancing tumor, non-enhancing tumor core, and surrounding nonenhancing T2/FLAIR hyperintensity. Models will be evaluated on separate validation and held-out test datasets using standardized metrics utilized across the BraTS 2023 series of challenges including the Dice similarity coefficient and Hausdorff distance. The models developed during the course of this challenge will aid in incorporation of automated meningioma MRI segmentation into clinical practice, which will ultimately improve care of patients with meningioma. △ Less

Submitted 12 May, 2023; originally announced May 2023.

The NLP Sandbox: an efficient model-to-data system to enable federated and unbiased evaluation of clinical NLP models

Authors: Yao Yan, Thomas Yu, Kathleen Muenzen, Sijia Liu, Connor Boyle, George Koslowski, Jiaxin Zheng, Nicholas Dobbins, Clement Essien, Hongfang Liu, Larsson Omberg, Meliha Yestigen, Bradley Taylor, James A Eddy, Justin Guinney, Sean Mooney, Thomas Schaffter

Abstract: Objective The evaluation of natural language processing (NLP) models for clinical text de-identification relies on the availability of clinical notes, which is often restricted due to privacy concerns. The NLP Sandbox is an approach for alleviating the lack of data and evaluation frameworks for NLP models by adopting a federated, model-to-data approach. This enables unbiased federated model evalua… ▽ More Objective The evaluation of natural language processing (NLP) models for clinical text de-identification relies on the availability of clinical notes, which is often restricted due to privacy concerns. The NLP Sandbox is an approach for alleviating the lack of data and evaluation frameworks for NLP models by adopting a federated, model-to-data approach. This enables unbiased federated model evaluation without the need for sharing sensitive data from multiple institutions. Materials and Methods We leveraged the Synapse collaborative framework, containerization software, and OpenAPI generator to build the NLP Sandbox (nlpsandbox.io). We evaluated two state-of-the-art NLP de-identification focused annotation models, Philter and NeuroNER, using data from three institutions. We further validated model performance using data from an external validation site. Results We demonstrated the usefulness of the NLP Sandbox through de-identification clinical model evaluation. The external developer was able to incorporate their model into the NLP Sandbox template and provide user experience feedback. Discussion We demonstrated the feasibility of using the NLP Sandbox to conduct a multi-site evaluation of clinical text de-identification models without the sharing of data. Standardized model and data schemas enable smooth model transfer and implementation. To generalize the NLP Sandbox, work is required on the part of data owners and model developers to develop suitable and standardized schemas and to adapt their data or model to fit the schemas. Conclusions The NLP Sandbox lowers the barrier to utilizing clinical data for NLP model evaluation and facilitates federated, multi-site, unbiased evaluation of NLP models. △ Less

Submitted 28 June, 2022; originally announced June 2022.

The RSNA-ASNR-MICCAI BraTS 2021 Benchmark on Brain Tumor Segmentation and Radiogenomic Classification

Authors: Ujjwal Baid, Satyam Ghodasara, Suyash Mohan, Michel Bilello, Evan Calabrese, Errol Colak, Keyvan Farahani, Jayashree Kalpathy-Cramer, Felipe C. Kitamura, Sarthak Pati, Luciano M. Prevedello, Jeffrey D. Rudie, Chiharu Sako, Russell T. Shinohara, Timothy Bergquist, Rong Chai, James Eddy, Julia Elliott, Walter Reade, Thomas Schaffter, Thomas Yu, Jiaxin Zheng, Ahmed W. Moawad, Luiz Otavio Coelho, Olivia McDonnell , et al. (78 additional authors not shown)

Abstract: The BraTS 2021 challenge celebrates its 10th anniversary and is jointly organized by the Radiological Society of North America (RSNA), the American Society of Neuroradiology (ASNR), and the Medical Image Computing and Computer Assisted Interventions (MICCAI) society. Since its inception, BraTS has been focusing on being a common benchmarking venue for brain glioma segmentation algorithms, with wel… ▽ More The BraTS 2021 challenge celebrates its 10th anniversary and is jointly organized by the Radiological Society of North America (RSNA), the American Society of Neuroradiology (ASNR), and the Medical Image Computing and Computer Assisted Interventions (MICCAI) society. Since its inception, BraTS has been focusing on being a common benchmarking venue for brain glioma segmentation algorithms, with well-curated multi-institutional multi-parametric magnetic resonance imaging (mpMRI) data. Gliomas are the most common primary malignancies of the central nervous system, with varying degrees of aggressiveness and prognosis. The RSNA-ASNR-MICCAI BraTS 2021 challenge targets the evaluation of computational algorithms assessing the same tumor compartmentalization, as well as the underlying tumor's molecular characterization, in pre-operative baseline mpMRI data from 2,040 patients. Specifically, the two tasks that BraTS 2021 focuses on are: a) the segmentation of the histologically distinct brain tumor sub-regions, and b) the classification of the tumor's O[6]-methylguanine-DNA methyltransferase (MGMT) promoter methylation status. The performance evaluation of all participating algorithms in BraTS 2021 will be conducted through the Sage Bionetworks Synapse platform (Task 1) and Kaggle (Task 2), concluding in distributing to the top ranked participants monetary awards of $60,000 collectively. △ Less

Submitted 12 September, 2021; v1 submitted 5 July, 2021; originally announced July 2021.

Comments: 19 pages, 2 figures, 1 table